-
Mashup Score: 17Remnant cholesterol, LDL cholesterol, and apoB absolute mass changes explain results of the PROMINENT trial. - 15 day(s) ago
The PROMINENT trial, a cardiovascular outcome trial of the triglyceride- and remnant cholesterol-lowering agent pemafibrate, has shown neutral results despite reduction in plasma triglycerides and remnant cholesterol. We tested the hypothesis that absolute mass changes in remnant cholesterol, LDL cholesterol, and apolipoprotein B explain the results of the PROMINENT trial.
Source: www.atherosclerosis-journal.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 27Lp(a) Awareness Day 2024 - 2 month(s) ago
Welcome to Lp(a) Awareness Day 2024! We’re excited to present this special issue of the EAS newsletter, dedicated to providing you with the latest updates and insights on lipoprotein(a).
Source: eas-society.orgCategories: General Medicine News, CardiologistsTweet-
Lp(a) Awareness Day 2024 #EAS. Valid every day ☀️ https://t.co/7T4Ihp1t8I
-
-
Mashup Score: 36Nomination step-by-step 2024 – EAS - 3 month(s) ago
Vacant positionsFrom January 16, until February 29, 2024, all EAS individual members are welcome to nominate candidates for six positions on the Executive Committee (EC) that will become vacant January 2025:Vice President (2025-2028)Secretary (2025-2028)Treasurer-Elect (Treasurer-Elect 2025, Treasurer 2026-2029)Ordinary Member responsible for Communication (2025-2028)Ordinary Member responsible…
Source: eas-society.orgCategories: General Medicine News, CardiologistsTweet-
Dear all, if you're a member of @society_eas, don't hesitate to nominate a certain @SABOURETCardio :) for the place of ordinary member for the COMMUNICATION. Teamwork with promising projects. #EAS. You may contact me in DM for more informations Link : https://t.co/N2d3luV6ot
-
-
Mashup Score: 1Anitschkow Prize – EAS - 7 month(s) ago
About the PrizeThe EAS Anitschkow Prize is the Society’s most prestigious distinction, awarded to outstanding scientists in the area of atherosclerosis and linked metabolic disturbances. The recipient of the Prize receives the Anitschkow Medal, an award of ten thousand Euros in recognition of their contribution to the study of atherosclerosis, presents the Anitschkow Lecture as part of the…
Source: eas-society.orgCategories: Cardiologists, Latest HeadlinesTweet-
#Anitschkow Prize #EAS Nominations are open https://t.co/yBOsk0TIzi
-
-
Mashup Score: 4Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society - 9 month(s) ago
In 2022, the European Atherosclerosis Society (EAS) published a new consensus statement on lipoprotein(a) [Lp(a)], summarizing current knowledge about its causal association with atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis. One of the novelties of this statement is a new risk calculator showing how Lp(a) influences lifetime risk for ASCVD and that global risk may be underestimated substantially in individuals with high or very high Lp(a) concentration. The statement also provides practical advice on how knowledge about Lp(a) concentration can be used to modulate risk factor management, given that specific and highly effective mRNA-targeted Lp(a)-lowering therapies are still in clinical development.
Source: www.atherosclerosis-journal.comCategories: Cardiologists, Latest HeadlinesTweet-
Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of #EAS after #ESCCongress if you have remaining questions… https://t.co/IaS89edE55
-
-
Mashup Score: 6Cardioimmunology: the new frontier! - 10 month(s) ago
Immunology has made it into the hearts of cardiologists. Just recently immunological questions concerning the heart were still considered inter-disciplinary. No
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet-
#Cardioimmunology: the new promising field. Brillant sessions during #EAS congress 2023 https://t.co/I7LlDw5xzs
-
-
Mashup Score: 0Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement - 11 month(s) ago
Abstract. This 2022 European Atherosclerosis Society lipoprotein(a) [Lp(a)] consensus statement updates evidence for the role of Lp(a) in atherosclerotic cardio
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet-
Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a #EAS consensus statement. #lipids #CVR https://t.co/6miujzWXr6
-
-
Mashup Score: 1Conference Calendar - The 91st EAS Congress - 1 year(s) ago
The congress will officially run on CET time zone (Central European Time) Legend Plenary (2) (2) Break (2) (2) Parallel Session (1) (1) Industry Session (2) (2) CME…
Source: cslide.ctimeetingtech.comCategories: Cardiologists, Latest HeadlinesTweet-
Conference Calendar - The 91st EAS Congress #EAS https://t.co/UtrWwuh8LC
-
-
Mashup Score: 0
The lipid-lowering landscape is rapidly evolving and several trials published this year provided new insights. The CORDIOPREV Trial was a Spanish single center
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet-
year in cardiovascular medicine 2022: the top 10 papers in #lipids #LLT with @LaleTokgozoglu and A. Catapano #EAS https://t.co/VcuE7AKtoZ
-
-
Mashup Score: 2ESC Congress 2022 Barcelona - 2 year(s) ago
How to manage patients with high LDL cholesterol Topic: Risk Factors and Prevention Session type: Symposium Date: 26 August Start time: 08:30 End time: 10:00 Room: Berlin Chairpersons Jane Armitage (University of Oxford – Oxford, United Kingdom of Great Britain & Northern Ireland) Anne Tybjaerg-Hansen (Rigshospitalet – Copenhagen University Hospital – Copenhagen, Denmark) PresentationsHow…
Source: esc365.escardio.orgCategories: Cardiologists, Latest HeadlinesTweet-
ESC Congress 2022 Barcelona how to manage high #LDL ? Experts from #EAS with @JohnKastelein among the speakers https://t.co/Mz2tb9FomB
-
Remnant cholesterol, LDL cholesterol, and apoB absolute mass changes explain results of the PROMINENT trial. By the elect President of #EAS et al https://t.co/Cgj9BssQCV